Harbin Pharmaceutical Group Co., Ltd.

SHSE:600664 Stock Report

Market Cap: CN¥7.5b

Harbin Pharmaceutical Group Future Growth

Future criteria checks 2/6

Harbin Pharmaceutical Group is forecast to grow earnings and revenue by 21.3% and 3.3% per annum respectively. EPS is expected to grow by 22.1% per annum. Return on equity is forecast to be 8.3% in 3 years.

Key information

21.3%

Earnings growth rate

22.15%

EPS growth rate

Pharmaceuticals earnings growth17.8%
Revenue growth rate3.3%
Future return on equity8.26%
Analyst coverage

Low

Last updated17 May 2026

Recent future growth updates

No updates

Recent updates

Analysis Article • Mar 17

Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Business And Shares Still Trailing The Market

Harbin Pharmaceutical Group Co., Ltd.'s ( SHSE:600664 ) price-to-earnings (or "P/E") ratio of 15.5x might make it look...
Analysis Article • Dec 31

Is Harbin Pharmaceutical Group (SHSE:600664) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 25

Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 27x, you may consider Harbin...
Analysis Article • Jun 25

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

Harbin Pharmaceutical Group Co., Ltd.'s ( SHSE:600664 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look...
Analysis Article • May 25

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Apr 17

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Investors weren't pleased with the recent soft earnings report from Harbin Pharmaceutical Group Co., Ltd. ( SHSE:600664...

Earnings and Revenue Growth Forecasts

SHSE:600664 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202817,491602N/A9861
12/31/202716,939520N/A1,0091
12/31/202616,403452N/A6881
3/31/202615,965310566718N/A
12/31/202515,964362289440N/A
9/30/202515,941449173280N/A
6/30/202516,158545467578N/A
3/31/202516,208665493599N/A
12/31/202416,176629692792N/A
9/30/202416,219613210323N/A
6/30/202415,895556400492N/A
3/31/202415,667450411496N/A
12/31/202315,457395863950N/A
9/30/202315,3125991,2181,284N/A
6/30/202315,096526925988N/A
3/31/202314,406487576650N/A
12/31/202213,809465532622N/A
9/30/202213,0534134137N/A
6/30/202212,812151-252-157N/A
3/31/202213,15638973166N/A
12/31/202112,802371-239-162N/A
9/30/202112,879-219-903-811N/A
6/30/202112,385-402-511-402N/A
3/31/202111,258-808-1,015-902N/A
12/31/202010,788-1,078-846-728N/A
9/30/202011,009-321-289-209N/A
6/30/202011,118-235-334-271N/A
3/31/202011,66114-162-107N/A
12/31/201911,82556N/A-285N/A
9/30/201911,174107N/A390N/A
6/30/201910,696-59N/A418N/A
3/31/201910,63061N/A372N/A
12/31/201810,814346N/A693N/A
9/30/201810,910386N/A197N/A
6/30/201811,484422N/A-36N/A
3/31/201811,790501N/A202N/A
12/31/201712,018407N/A149N/A
9/30/201712,993441N/A598N/A
6/30/201713,180757N/A1,110N/A
3/31/201713,761737N/A1,833N/A
12/31/201614,127788N/A2,778N/A
9/30/201613,662789N/A3,179N/A
6/30/201613,830584N/A3,553N/A
3/31/201614,435515N/A2,929N/A
12/31/201515,856580N/A1,660N/A
9/30/201516,038324N/A899N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600664's forecast earnings growth (21.3% per year) is above the savings rate (2.4%).

Earnings vs Market: 600664's earnings (21.3% per year) are forecast to grow slower than the CN market (27.9% per year).

High Growth Earnings: 600664's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600664's revenue (3.3% per year) is forecast to grow slower than the CN market (17.1% per year).

High Growth Revenue: 600664's revenue (3.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600664's Return on Equity is forecast to be low in 3 years time (8.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/30 17:04
End of Day Share Price 2026/06/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Harbin Pharmaceutical Group Co., Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wayne HeChina Stock Investment Research Co. Ltd. (GZ500..com)
null Research DepartmentGuotai Haitong/Guotai Junan International Holdings Limited
Wen DaiHuatai Research